The main question that sits at the center of the most common licensing questions and obstacles for cell and gene strategies: how do companies license a product that is often never touched by the parties that need to hold the license?

Ryan Fields, Sr. Vice President of Regulatory Services at Two Labs answers this question and more in his article featured on Pharmaceutical Outsourcing.

Read more here.